AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
AMZN   2,421.86 (-0.62%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
BAC   24.28 (+7.15%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
AMZN   2,421.86 (-0.62%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
BAC   24.28 (+7.15%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
AMZN   2,421.86 (-0.62%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
BAC   24.28 (+7.15%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
AMZN   2,421.86 (-0.62%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
BAC   24.28 (+7.15%)
Log in

Best Stocks Under $10.00 for 2020

A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks under 10 dollars, there are some important things to know.

SHOULD I BUY STOCKS UNDER $10?

The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable.

The problem with this approach is it assumes “high price good, low price bad.” And in fairness, that can be true. And you should not read another word of this article without internalizing this simple truth. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth.

So the first thing I would say to investors looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish.

But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals.

And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you.

But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend.

You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market.

HOW IS A COMPANY’S SHARE PRICE CALCULATED?

If you’re a more experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions.

To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for.

The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought.

To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares.

Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10.

The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company.

Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59.

66.37/8.74 = 7.59

This means at that moment, one share of GE stock was valued at $7.59.

WHY DO COMPANIES ISSUE SHARES?

Remember earlier when looked at the example of two companies that were both valued at $100 million. Why would one company have 100 million shares available and the other only 1 million?

First of all, if you’re asking that question good for you. You’re on your way to being a sound investor. But understanding the answer is equally important. So let’s go back to the basics so you understand why companies issue shares.

Companies issue shares as a way to raise money that they don’t have to pay back. This is because, unlike a loan where a company borrows money from a financial institution or hedge fund, shares are bought and sold by other investors. That’s why it’s an investment, right? An investor is giving the company money (in the form of share purchases) in return for the chance that the share price will go higher. This means the value of the company will rise.

So in the earlier example, the company that only has 1 million shares outstanding has a higher demand for its stock. Therefore, if all things are equal (i.e. the market cap of the two companies are the same), that company’s stock will be more valuable.

WHAT ARE THE REWARDS OF STOCKS UNDER $10?

The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were

That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment.

That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could only buy about five shares of Amazon (NASDAQ:AMZN). But they could buy over 150 shares of Lovesac (NASDAQ:LOVE), a furniture retailer that is currently trading below $7 a share.

This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks.

WHAT ARE THE RISKS OF STOCKS UNDER $10?

One of the risks of buying a stock that is priced under $10 is the risk of share dilution. Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers. In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.

However, when a company gets into financial trouble, it becomes difficult for them to get loans. Think of your personal finances. If you are looking to finance a car or a house, banks want to make sure you have enough available cash on a monthly basis so you can make the payment.

It’s no different for a company. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.

When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further.

Issuing new shares is different from a stock split. A company that offers a stock split is simply trying to make its stock less expensive for retail (individual) investors. But when a company issues a split, they are giving current shareholders more shares at a lower price (e.g. an investor that owned 100 shares at $40 now owns 200 shares at $20).

Another risk with buying stocks under $10 includes the risk of increased competition. Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels.

Yet another risk to buying stocks under $10 is that they may be in a cyclical industry. A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink.

A final risk to consider is the stock is what it is, a low- to no-growth stock. If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend.

WHAT ARE THE BEST STOCKS UNDER $10?

If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-off’s in history.

On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price.

Stocks Under 10 Dollars

Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value.

One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider.

Avid Bioservices logo

#1 - Avid Bioservices

NASDAQ:CDMO
Stock Price: $5.27 (-$0.02)
PE Ratio: -27.74
Market Cap: $298.79 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.50 (80.3% Upside)
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and Current Good Manufacturing Practices (CGMP) commercial manufacturing services focused on biopharmaceutical products derived from mammalian cell culture for biotechnology and pharmaceutical companies. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory submission and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Ocular Therapeutix logo

#2 - Ocular Therapeutix

NASDAQ:OCUL
Stock Price: $6.84 (-$0.38)
PE Ratio: -3.49
Market Cap: $385.29 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.60 (25.7% Upside)
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Flexion Therapeutics logo

#3 - Flexion Therapeutics

NASDAQ:FLXN
Stock Price: $9.69 (-$0.08)
PE Ratio: -2.56
Market Cap: $376.73 million
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $23.75 (145.1% Upside)
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Viking Therapeutics logo

#4 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $7.74 (-$0.21)
PE Ratio: -18.43
Market Cap: $588.26 million
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.56 (88.1% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Ardelyx logo

#5 - Ardelyx

NASDAQ:ARDX
Stock Price: $7.67 (-$0.42)
PE Ratio: -5.85
Market Cap: $698.98 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (56.5% Upside)
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
NeuBase Therapeutics logo

#6 - NeuBase Therapeutics

NASDAQ:NBSE
Stock Price: $8.00 (-$0.26)
Market Cap: $191.42 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $15.60 (95.0% Upside)
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Corbus Pharmaceuticals logo

#7 - Corbus Pharmaceuticals

NASDAQ:CRBP
Stock Price: $8.01 (-$0.05)
PE Ratio: -7.09
Market Cap: $584.27 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $39.80 (396.9% Upside)
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
SilverCrest Metals logo

#8 - SilverCrest Metals

NASDAQ:SILV
Stock Price: $8.05 (-$0.66)
Market Cap: $1.09 billion
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.60 (31.7% Upside)
SilverCrest Metals Inc. engages in the acquisition, exploration, and development of precious metal properties. It primarily explores for silver and gold properties. The company's principal property is the Las Chispas project that consists of 27 concessions totaling approximately 1,389 hectares located in Sonora, Mexico. SilverCrest Metals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Ovid Therapeutics logo

#9 - Ovid Therapeutics

NASDAQ:OVID
Stock Price: $6.69 (+$0.84)
PE Ratio: -4.49
Market Cap: $320.31 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (109.3% Upside)
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Asure Software logo

#10 - Asure Software

NASDAQ:ASUR
Stock Price: $6.24 (-$0.55)
PE Ratio: 3.10
Market Cap: $104.08 million
P/E Ratio: 3.1
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.83 (57.6% Upside)
Asure Software, Inc. provides cloud-based human capital management and workspace management solutions worldwide. Its product line includes AsureSpace workspace management solutions that enable organizations to optimize their real estate investment, and create a digital workspace that empowers mobile and virtual employees; and AsureForce time and labor management solutions to help organizations optimize their workforce, as well as control labor administration costs and activities. The company also offers AsureHCM, an integrated cloud-based solution that provides human resource (HR) management and payroll to benefits, talent acquisition, and performance management services; Evolution HCM, an integrated payroll, HR, and tax management suite; and AsureConsulting, which offers a suite of services to assist organizations through the entire employee lifecycle. In addition, it provides SmartView occupancy sensors and analytics platform that offers insights, which allow companies to make strategic decisions about real estate investments and workplace design; and SmartMove, a move management software that help companies design floorplans and track permanent seat assignments, as well as manage assets, such as telephones, laptops, desks, chairs, and other items assigned to an employee. Further, the company provides AsureSpace Resource Scheduler, a solution for the digital workplace that features conference room and desk reservations, service management, interactive floorplans, visitor management, calendar and Web conference integrations, and reporting; and NowSpace, a mobile app for Apple and Android devices that enables mobile workers to find and reserve desks and conference rooms from their smart phones. It serves clients ranging from Fortune 500 to small and mid-sized businesses directly, as well as through reseller and referral partners. Asure Software, Inc. was founded in 1985 and is headquartered in Austin, Texas.
Chiasma logo

#11 - Chiasma

NASDAQ:CHMA
Stock Price: $6.65 (-$0.16)
PE Ratio: -6.05
Market Cap: $287.83 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.00 (95.5% Upside)
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
CECO Environmental logo

#12 - CECO Environmental

NASDAQ:CECE
Stock Price: $5.25 (-$0.10)
PE Ratio: 9.72
Market Cap: $182.99 million
P/E Ratio: 9.7
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.60 (82.9% Upside)
CECO Environmental Corp. provides industrial air quality and fluid handling systems for the energy, industrial, and other markets worldwide. The company operates through three segments: Energy Solutions, Industrial Solutions, and Fluid Handling Solutions. The company engineers, designs, builds, and installs systems that capture, clean, and destroy airborne contaminants from industrial facilities, as well as equipment that control emissions from such facilities; and fluid handling and filtration systems. Its products and services include dampers and diverters, selective catalytic reduction and selective non-catalytic reduction systems, cyclonic technology, thermal oxidizers, filtration systems, scrubbers, and fluid handling equipment, as well as plant engineering services and engineered design build fabrication. The company markets its products and services to natural gas processors, transmission and distribution companies, refineries, power generators, boiler manufacturers, compressor manufacturers, metals and minerals, industrial manufacturing, and engineering and construction companies. CECO Environmental Corp. was founded in 1966 and is headquartered in Dallas, Texas.
Gamida Cell logo

#13 - Gamida Cell

NASDAQ:GMDA
Stock Price: $5.73 (+$0.43)
PE Ratio: -2.97
Market Cap: $128.38 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.33 (185.0% Upside)
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Village Farms International logo

#14 - Village Farms International

NASDAQ:VFF
Stock Price: $5.85 (+$0.65)
PE Ratio: 146.25
Market Cap: $292.50 million
P/E Ratio: 146.3
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.50 (96.6% Upside)
Village Farms International, Inc., together with its subsidiaries, produces, markets, and distributes greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. The company operates in two segments, Produce Business and Energy Business. It also owns and operates a 7.0 megawatt power plant that generates and sells electricity to British Columbia Hydro and Power Authority. Village Farms International, Inc. markets and distributes its products under the Village Farms brand name to retail supermarkets and fresh food distribution companies, as well as products produced under exclusive arrangements with other greenhouse producers. The company was formerly known as Village Farms Canada Inc. and changed its name to Village Farms International, Inc. in December 2009. Village Farms International, Inc. was founded in 1989 and is based in Delta, Canada.
NuCana logo

#15 - NuCana

NASDAQ:NCNA
Stock Price: $5.92 (+$0.05)
PE Ratio: -7.49
Market Cap: $196.83 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.67 (215.3% Upside)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Calithera Biosciences logo

#16 - Calithera Biosciences

NASDAQ:CALA
Stock Price: $6.10 (-$0.21)
PE Ratio: -3.53
Market Cap: $441.68 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.50 (39.3% Upside)
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Digital Turbine logo

#17 - Digital Turbine

NASDAQ:APPS
Stock Price: $6.11 (+$0.29)
PE Ratio: -67.88
Market Cap: $517.84 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.35 (36.7% Upside)
Digital Turbine, Inc., through its subsidiaries, provides media and mobile communication products and solutions for mobile operators, application developers, device original equipment manufacturers (OEMs), and other third parties worldwide. It provides Ignite, a software platform that enables mobile operators and OEMs to control, manage, and monetize devices. The company offers other products and professional services directly related to the Ignite platform. Digital Turbine, Inc. is headquartered in Austin, Texas.
Paratek Pharmaceuticals logo

#18 - Paratek Pharmaceuticals

NASDAQ:PRTK
Stock Price: $4.40 (-$0.17)
PE Ratio: -1.26
Market Cap: $194.95 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.50 (320.5% Upside)
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
PhaseBio Pharmaceuticals logo

#19 - PhaseBio Pharmaceuticals

NASDAQ:PHAS
Stock Price: $4.49 (+$0.05)
PE Ratio: -2.74
Market Cap: $127.78 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (145.0% Upside)
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Baudax Bio logo

#20 - Baudax Bio

NASDAQ:BXRX
Stock Price: $4.36 (+$0.33)
PE Ratio: -1.25
Market Cap: $70.80 million
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.00 (198.2% Upside)
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.